Shanghai Fosun Pharmaceutical (Group) Co., Ltd. v. Hajjar

District Court, S.D. New York·Decided December 1, 2023·No. 1:22-cv-08269·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD., Petitioner, Case No. 1:22-cv-08269 (JLR) -against- MEMORANDUM OPINION AND ORDER DR. JOHN HAJJAR, et al., Respondents. JENNIFER L. ROCHON, United States District Judge: Petitioner Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun”) seeks confirmation of an arbitration award and pre-judgment and post-judgment interest against Respondents Dr. John Hajjar (“Dr. Hajjar”), Sovereign Medical Services, Inc. (“SMS”) and Sovereign Capital Holdings, LLC (“SCH”) (together, “Respondents”). ECF No. 21 (the “Amended Petition” or “Am. Pet.”). Respondents moved to vacate the arbitration award and dismiss the Amended Petition. Because the case is stayed as to Dr. Hajjar, this order applies only to Respondents SMS and SCH. For the following reasons, Fosun’s Amended Petition and motion to confirm the arbitration award against SMS and SCH is GRANTED, and SMS and SCH’s motion to vacate the arbitration award is DENIED. BACKGROUND I. The Agreements The following facts are taken from Fosun’s Amended Petition. See Am. Pet. On March 10, 2015, Fosun and SMS entered into two agreements: The Stock Purchase Agreement (the “SPA”) and the Investor Rights Agreement (the “IRA”) (together, the “Agreements”). Id. ¶ 6. Pursuant to the Agreements, Fosun purchased shares of common stock in SMS. Id. ¶ 7. As part of that transaction, Fosun bargained for certain protections, including the right to exercise a put option if SMS failed to achieve certain financial milestones (the “Put Option”). Id. If SMS’s Consolidated Adjusted EBITDA (as defined in the SPA) for a given fiscal year fell below the Target EBITDA (also defined in the SPA) by at least 10%, then Fosun could exercise the Put Option. Id. ¶ 8. The Put Option allowed Fosun

to elect SMS, SCH, or Dr. Hajjar to purchase some or all of its shares at a price per share equal to the original price paid by Fosun plus 5% annual compounded interest accruing from January 1 of the first year in which SMS failed to achieve the required financial milestones until the date of the actual payment (the “Put Price”). Id. If Fosun decided to exercise the Put Option, it was required to deliver a written notice to SMS (the “Put Option Notice”). Id. The Put Option was due and payable to Fosun within 30 days of the delivery of the Put Option Notice. Id. SMS’s Consolidated Adjusted EBITDA fell below the Target EBITDA by at least 10% in both 2016 and 2017. Id. ¶ 9. On January 15, 2019, Fosun sent SMS a Put Option Notice. Id. ¶ 10. Respondents failed to pay Fosun the amount required by the exercise of the

Put Option within 30 days of the Put Option Notice’s delivery. Id. ¶ 11. II. The Arbitration The IRA and SPA each contained binding arbitration clauses and New York choice- of-law provisions. Id. ¶¶ 12-13. On February 19, 2019, Fosun filed a demand for arbitration against Respondents with the American Arbitration Association (“AAA”) to recover the Put Price. Id. ¶ 14. Fosun demanded its initial investment amount of $40 million plus 5% annual compound interest from January 1, 2016, as well as attorney’s fees, interest, and arbitration costs. Id. Following discovery and briefing, an arbitration hearing was held on July 13-14, 2021, during which the parties presented fact and expert testimony. Id. ¶¶ 15-20. After the hearing, the parties submitted post-hearing briefs to the arbitrator. Id. ¶ 21. On December 10, 2021, the arbitrator issued an Interim Award in favor of Fosun (the “Interim Award”), providing that Fosun was entitled to the Put Price of $40 million plus compound interest on that amount at 5% running from January 1, 2017. Id. ¶¶ 22-25. The Interim Award provided that Fosun is entitled to elect which of the Respondents perform that

redemption. Id. ¶ 25. The Interim Award also noted that the prevailing party is entitled to recover its fees and costs (including attorney’s fees) from the other party or parties. Id. ¶ 26. Fosun submitted a formal request for attorney’s fees and costs on January 14, 2022; that same day, Respondents filed objections to the Interim Award. Id. ¶ 27. The parties subsequently submitted further briefing on the issues. Id. On May 25, 2022, the arbitrator issued a second interim award, which denied Respondents’ objections to the Interim Award and established that the only outstanding issue was Fosun’s request for fees, costs, and disbursements (“Second Interim Award”). Id. ¶ 28. Following further correspondence and additional submissions, on July 6, 2022, the arbitrator deemed the record full and closed. Id. ¶¶ 29-31.

On August 5, 2022, the arbitrator issued final award (the “Final Award”). Id. ¶ 32. The Final Award determined, among other things, that Fosun was entitled to the Put Price of $40 million plus compound interest on that amount at 5% running from January 1, 2017, and that Fosun was entitled to elect which of the three Respondents perform that redemption. Id. ¶ 34. The Final Award also awarded Fosun fees, costs, disbursements, administrative fees, and arbitrator compensation, for which the three Respondents were jointly and severally liable. Id.; see also id. ¶¶ 36-38 (describing post-Final Award briefing and clarifications from the arbitrator). Following the correction of a clerical error, the Final Award entitled Fosun to the Put Price of $40 million, plus interest on that amount at a rate of 5% per annum calculated daily running from January 1, 2017, plus $1,437,051.67 in attorney’s fees, $419,821.46 in costs and disbursements, and $190,637.50 for the reimbursement of AAA administrative fees and arbitrator compensation. Id. ¶¶ 32-38. III. The Present Action On October 11, 2022, Fosun filed the Amended Petition pursuant to section 9 of the Federal Arbitration Act (the “FAA”). Am. Pet. On November 1, 2022, Fosun moved to

confirm the arbitration award. ECF No. 27. On November 4, 2022, Respondents moved to vacate the arbitration award and dismiss the Amended Petition. ECF Nos. 32-33. On December 6, 2022, Fosun opposed Respondents’ motion to vacate the arbitration award and replied in further support of its Amended Petition. ECF Nos. 35-36. Respondents replied on December 20, 2022. ECF No. 37. On January 4, 2023, Respondents filed a letter requesting oral argument and noting that Fosun declined to consent to their request. ECF No. 38.1 On June 22, 2023, Fosun submitted a letter alerting the Court that Dr. Hajjar had filed for Chapter 11 bankruptcy on June 9, 2023, and that this action was therefore automatically stayed as to Dr. Hajjar but not as to the two remaining Respondents, SMS and SCH. ECF

No. 39. On June 23, 2023, the law firm Frier Levitt, LLC filed a motion to withdraw as counsel of record for all Respondents. ECF No. 43. On July 17, 2023, the Court granted the motion for Frier Levitt, LLC to withdraw as counsel of record, subject to the firm first serving the Court’s order on Respondents and filing

1 The Court declines to hold oral argument. SMS and SCH are no longer represented by counsel and cannot proceed pro se, as further explained herein. Moreover, the briefing that the Court considered was sufficient and oral argument would not materially assist the Court. See Dotson v. Griesa, 398 F.3d 156, 159 (2d Cir. 2005) (noting that “a district court acts well within its discretion in deciding dispositive motions on the parties’ written submissions without oral argument”). a letter with Respondents’ contact information. ECF No. 44. The Court also advised that SMS and SCH cannot proceed pro se as corporate entities, ordered SMS and SCH to retain replacement counsel, and directed counsel to file a notice of appearance by August 14, 2023. Id. No notice of appearance for counsel for SMS and SCH was filed by that date.

Free access — add to your briefcase to read the full text and ask questions with AI

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. v. Hajjar, (S.D.N.Y. 2023).

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. v. Hajjar (Shanghai Fosun Pharmaceutical (Group) Co., Ltd. v. Hajjar) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Florasynth, Inc. v. Alfred Pickholz
750 F.2d 171 (Second Circuit, 1984)
Landau v. Eisenberg
922 F.3d 495 (Second Circuit, 2019)
NYCTL 1998-2 Trust v. Wagner
61 A.D.3d 728 (Appellate Division of the Supreme Court of New York, 2009)
Dotson v. Griesa
398 F.3d 156 (Second Circuit, 2005)
D.H. Blair & Co. v. Gottdiener
462 F.3d 95 (Second Circuit, 2006)
Lattanzio v. Comta
481 F.3d 137 (Second Circuit, 2007)